Letter: Prolonged Treatment with Sirolimus (Rapamycin) for Graves’ Orbitopathy

Abstract

Get full access to this article

View all access options for this article.

References

Lanzolla

, Maglionico

, Comi

, et al. Sirolimus as a second-line treatment for Graves’ orbitopathy. J Endocrinol Invest, 2022; 45(11):2171–2180; doi: 10.1007/s40618-022-01862-y

Comi

, Cosentino

, Lanzolla

, et al. Long-term outcome of Graves’ orbitopathy following treatment with sirolimus. J Endocrinol Invest, 2025; 48(3):607–618; doi: 10.1007/s40618-024-02470-8

Bartalena

, Kahaly

, Baldeschi

, et al.; EUGOGO. The 2021 European group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol, 2021; 185(4):G43–G67; doi: 10.1530/EJE-21-0479

Cosentino

, Lanzolla

, Comi

, et al. Ablative versus conservative approach for hyperthyroidism treatment in patients with Graves’ orbitopathy: A retrospective cohort study. Thyroid, 2025; 35(3):298–306; doi: 10.1089/thy.2024.0633